<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Damora Therapeutics, Inc. — News on 6ix</title>
    <link>https://6ix.com/company/damora-therapeutics-inc</link>
    <description>Latest news and press releases for Damora Therapeutics, Inc. on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Mon, 30 Mar 2026 12:00:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/damora-therapeutics-inc" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo69d74b0151cc36e475333dc5.webp</url>
      <title>Damora Therapeutics, Inc.</title>
      <link>https://6ix.com/company/damora-therapeutics-inc</link>
    </image>
    <item>
      <title>Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)</title>
      <link>https://6ix.com/company/damora-therapeutics-inc/news/damora-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4</link>
      <guid isPermaLink="true">https://6ix.com/company/damora-therapeutics-inc/news/damora-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4</guid>
      <pubDate>Mon, 30 Mar 2026 12:00:00 GMT</pubDate>
      <description>BOSTON, March 30, 2026 (GLOBE NEWSWIRE) -- Damora Therapeutics, Inc. (NASDAQ: DMRA) (“Damora”), a biotechnology company working to fundamentally redefine care for patients with blood disorders, today announced that it granted equity awards to four newly-hired, non-executive employees on March 24, 2026 and to its newly-hired President and Chief Executive Officer, Jennifer Jarrett, on March 30, 2026. The inducement grants were approved by Damora’s Board of Directors or its independent Compensation</description>
    </item>
    <item>
      <title>Damora Therapeutics Appoints Biotechnology Leader Jennifer Jarrett as President and Chief Executive Officer; Adds Two Industry Veterans to Board of Directors</title>
      <link>https://6ix.com/company/damora-therapeutics-inc/news/damora-therapeutics-appoints-biotechnology-leader-jennifer-jarrett-as-president-and-chief-executive-officer-adds-two-industry-veterans-to-board-of-directors</link>
      <guid isPermaLink="true">https://6ix.com/company/damora-therapeutics-inc/news/damora-therapeutics-appoints-biotechnology-leader-jennifer-jarrett-as-president-and-chief-executive-officer-adds-two-industry-veterans-to-board-of-directors</guid>
      <pubDate>Mon, 23 Mar 2026 12:00:00 GMT</pubDate>
      <description>-- Ms. Jarrett brings nearly three decades of executive leadership in biotech, tech and finance -- -- Biotech leaders Dr. Cameron Turtle and Mike Landsittel appointed to Board of Directors -- -- Peter Harwin named Chairman of the Board of Directors -- BOSTON, March 23, 2026 (GLOBE NEWSWIRE) -- Damora Therapeutics, Inc. (NASDAQ: DMRA), a biotechnology company working to fundamentally redefine care for patients with blood disorders, today announced that its Board of Directors has appointed Jennife</description>
    </item>
    <item>
      <title>Damora Therapeutics Reports Full-Year 2025 Financial Results and Recent Corporate Highlights</title>
      <link>https://6ix.com/company/damora-therapeutics-inc/news/damora-therapeutics-reports-full-year-2025-financial-results-and-recent-corporate-highlights</link>
      <guid isPermaLink="true">https://6ix.com/company/damora-therapeutics-inc/news/damora-therapeutics-reports-full-year-2025-financial-results-and-recent-corporate-highlights</guid>
      <pubDate>Thu, 19 Mar 2026 20:10:00 GMT</pubDate>
      <description>-- DMR-001 on track for IND or CTA submission in mid-2026, with two clinical proof-of-concept datasets expected beginning mid-2027 -- -- Strong financial position with approximately $535 million in cash and cash equivalents as of February 28, 2026, expected to fund operations into Phase 3 development of DMR-001 -- BOSTON, March 19, 2026 (GLOBE NEWSWIRE) -- Damora Therapeutics, Inc. (formerly Galecto, Inc.) (“Damora” or the “Company”) (NASDAQ: DMRA), a biotechnology company working to fundamental</description>
    </item>
  </channel>
</rss>